Ivy Brain Tumor Center and SonALAsense Announce Positive Initial Results

The Ivy Brain Tumor Center at Barrow Neurological Institute and SonALAsense announced positive results in their first-in-human Phase 0/1 clinical trial of SDT in recurrent glioblastoma patients. The initial results were presented at the European Society for Medical Oncology Congress today by Nader Sanai, MD, Director of the Ivy Brain Tumor Center. “The Ivy Center’s Phase 0/1 study has shown a promising translation of the preclinical results of SDT in patients with glioblastoma.

p3_admin

September 21, 2021

Limitations of the Standard of Care for Patients with Brain Tumors

Since I started my training, there was the establishment of what’s currently the standard of care. Which is the concurrent use of radiation and temozolomide and adjuvant temozolomide. That, unfortunately, has not changed though, in the last 15 years. So although I got to see the transformation of the field and maybe for the first time, a large number of patients who have five years and beyond survival, we still have not been able to really make that a reality for a majority of patients. So we’ve unfortunately had some limitations in the advancements since that time.

p3_admin

September 10, 2021

Categories
Audience Categories
BFTC Categories
Journey Phase Categories
Topic Categories
Subtopic Categories
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29